Ionis Pharmaceuticals Inc. (IONS) saw an uptrend of 1.74% in the recent trading with $62.10 being its most recent. The current price level -3.48% lower than the highest price of $64.34 marked by the stock while trading over the past 52-weeks, whereas it is 57.93% higher than the lowest price of $39.32 the company dropped to over past 52-weeks. The latest news story on IONS appeared in GlobeNewswire under the title “Biogen Announces First Patient Treated in RESPOND Study Evaluating Benefit of SPINRAZA® (nusinersen) in Patients Treated With Zolgensma® (onasemnogene abeparvovec)” on Jan-08-21.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Squeezing the time span to 30 day period shows us the stock is currently trading -0.32% below one month high and is +33.49% above of the lowest during that time. Looking into the simple moving average, Ionis Pharmaceuticals Inc. (IONS)’s stock stands at a SMA-50 of $52.04 while that of 5-day is reading $58.88.
Daily rise and fall of price influence many of the traders, and in order to overcome the fluctuating effect of that and to watch the stock closely, traders focus more on stock’s 200-day moving average. At various points in trading activity, investors are more likely to be making use of that measure as a strong indicator in figuring out their support and resistance levels, and IONS’s SMA-200 as of now is $53.73.
Coming around sales and income figures, publically trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor. Ionis Pharmaceuticals Inc. (IONS) last released financial results for the quarter that ended 9/29/2020, posting a surprise factor of -144.40% for net revenue. During the reported three-month period, company’s sales were $160.08 billion while analysts on average were estimating the same to be $272.31 million.
The perspective of Ionis Pharmaceuticals Inc. (NASDAQ:IONS)’s current quarter earnings identifies that analysts are in consensus over the estimate of -0.09 for stock’s EPS in the current quarter. 17 analysts covering the stock at Wall Street were agreed upon that EPS consensus. Company’s EPS for the last quarter was -0.22.
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 139.71 million. IONS does have institutional investors; and they hold 86.70% or $32664.6 of the stock.
Moreover, the latest SEC filings also revealed that stock came across 21 new insider purchases involving 183,736 shares. On the other hand, IONS declared 327,985 shares have been sold in 30 insider transactions over the past three months.
As on Sep 29, 2020, FMR, LLC was the top most holder in Ionis Pharmaceuticals Inc. (NASDAQ:IONS) with an ownership of 20.87 million shares of the company or 14.92% of the stake worth $990.14 million. The filing also reveals Vanguard Group, Inc. (The) as the second largest holder in the company with a control over 8.58% of the outstanding shares. Its stake is worth $568.93 million for having 11.99 million shares in hand.
Price (T.Rowe) Associates Inc also came holding a key position in the company during the recent quarter and it now holds 7.68% of the outstanding shares. With this there are now 526 institutions which have possession in IONS’s shares.
Investors are for sure keenly observing the recommendations of analysts at Wall Street about the Ionis Pharmaceuticals Inc. And review of current evaluations agreed by the analysts discloses a Buy rating for IONS. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 2.60 for the stock. Lower value of between 0 and 2 implies a Buy recommendation whereas the value in the range of 2 to 3 suggests Hold while above 3 recommends the investors to Sell the stock. Currently, the stock has been recommended as Moderate Buy by 23 of the Wall Street analysts.
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, current ratio recorded by Ionis Pharmaceuticals Inc. was 9.97 while posting a debt to equity ratio of 0.59. The count was 53.40 for long-term debt to equity ratio.
Ionis Pharmaceuticals Inc.’s return on equity, or ROE, is 5.30%, compared to the industry average of -46.13% for Healthcare – Biotechnology. Although this indicates that IONS uses its equity well, the metric will vary significantly depending on the industry.
To comprehend better with the trade moves and investors’ behavior, exploring the short, medium and long term technical indicators along with average volume of a stock is an effective way to make use of. When looking into those indicators for Ionis Pharmaceuticals Inc. (IONS), we notice that the stock’s 20-day average volume is at 1,472,925 shares and 100% of short term indicators are suggesting the stock as Buy. Its 50-day average volume of 1,164,534 shares. And to end, IONS’s 100-day average volume is 1,079,428 shares with 50% of the long-term indicators pointing towards Buy for the stock.